the No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention (PCI)

NCT04835974 | Unknown

• 1 other identifier: No-reflow phenomenon
• Study Type: interventional
• Target: 120
• Locations: 0 countries
• Sites: N/A

Brief Summary

1- to find metabolic factors that correlate with the development of no reflow phenomenon that may help prevent its occurrence .

Conditions

No-Reflow Phenomenon

Outcome Measures

Primary Outcomes (1)

• measure serum random blood sugar

  to detect the correlation between the diabetus mellitus (serum random blood sugar) and no-reflow phenomenon and analysis of this metabolic factors in patient withSTEMI who will undergo primaru PCI and show its effects on no-reflow phenomenon that may help prevent its occurrence .

  baseline

Secondary Outcomes (2)

• measure the serum uric acid

  baseline

• measure the lipid profile

  baseline

Study Arms (1)

diabetic patients with reflow phenomenon

EXPERIMENTAL

All Assiut University heart Hospital patients ,and who meet the listed inclusion and exclusion criteria will be eligible for the study. Patients' charts will be retrieved based on their intervention procedures. The charts will be reviewed and eligible patients will be filtered. The needed variables will be entered into our data base for later data analysis.

Diagnostic Test: 1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S

Interventions

1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S DIAGNOSTIC_TEST

Blood samples were obtained before PCI, and the following parameters will be measured: 1. LDL-C (low-density lipoprotein cholesterol)\| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2. Glycemia will be assessed : RBS ( random blood sugar ) . 3. Serum Uric acid : S .UA

diabetic patients with reflow phenomenon

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• diabetic patients with STEMI treated with primary PCI

You may not qualify if:

• non diabetic . with selected PCI
• (1) a history of an unprotected left main artery with severe liver and kidney diseases or coronary artery bypass grafting .
• (2) patients who had valvular disease or cardiomyopathy . (3) severe dissection, thromboembolism in other parts, or vasospasm; and known malignancy .
• (4) patients with contraindications for anticoagulant therapy, such as active visceral hemorrhage, hemorrhagic stroke, or ischemic stroke within half a year (including transient ischemic attack), or aortic dissection, or patients with hematological diseases complicated with coagulation disorders .

Sponsors & Collaborators

• Assiut University: lead

Related Publications (1)

• Bernstein JM, Lee J, Conboy K, Ellis E, Li P. The role of IgE mediated hypersensitivity in recurrent otitis media with effusion. Am J Otol. 1983 Jul;5(1):66-9. No abstract available.

  PMID: 6683937 BACKGROUND

MeSH Terms

Conditions

No-Reflow Phenomenon

Condition Hierarchy (Ancestors)

Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

alzahraa gamal, master

CONTACT

01026181748; alzahraagamal@gmail.com

hatem abdel elrahman

CONTACT

01005212162; Hatem19652006@yahoo.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Metabolic profile as a predictor of no reflow in diabetic patients treated with primary Percutaneous Coronary Intervention (PCI) .

Study Record Dates

• First Submitted: March 23, 2021
• First Posted: April 8, 2021
• Study Start: May 1, 2021
• Primary Completion: May 1, 2022
• Study Completion: May 1, 2022
• Last Updated: April 14, 2021

Record last verified: 2021-04